Russell Investments Group’s Lyell Immunopharma LYEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.6K Buy
+752
New +$13.6K ﹤0.01% 3922
2024
Q3
– Sell
-574
Closed -$16.6K – 3748
2024
Q2
$16.6K Buy
574
+403
+236% +$19.2K ﹤0.01% 2972
2024
Q1
$7.62K Buy
+171
New +$7.32K ﹤0.01% 2884
2023
Q3
– Sell
-1,065
Closed -$67.7K – 3583
2023
Q2
$67.7K Sell
1,065
-2,472
-70% -$137K ﹤0.01% 2676
2023
Q1
$167K Buy
+3,537
New +$189K ﹤0.01% 2506

Other funds holding LYEL

Russell Investments Group's LYEL Position: Q2 2026 in Review

Russell Investments Group opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 752 shares worth $10.6K. The stake represents ﹤0.01% of the portfolio and ranks #3922 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in LYEL as recently as Q2 2024.

Russell Investments Group first reported a position in LYEL in Q1 2023 and has held it in 5 quarters since. The position peaked at $167K in Q1 2023. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Russell Investments Group held 752 shares of Lyell Immunopharma worth $10.6K as of Q2 2026.
  • Lyell Immunopharma was a new Russell Investments Group position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3922 holding.
  • Russell Investments Group first reported a position in Lyell Immunopharma in Q1 2023 and has held it in 5 quarters since.
  • Russell Investments Group's Lyell Immunopharma position peaked at $167K in Q1 2023.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.